Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
Willing and able to comply with clinic visits and study-related procedures as per protocol
Provide informed consent signed by study patient or legally acceptable representative
Able to understand and complete study-related questionnaires as per protocol
You may not be if
Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
Any previous treatment with DUPIXENT® for any condition
Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol
Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol
Clareo Health | Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
